Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR3419 + rituximab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAR3419 + rituximab is a combination therapy used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. SAR3419 (coltuximab ravtansine) is an antibody-drug conjugate composed of an anti-CD19 humanized monoclonal antibody linked to the cytotoxic agent DM4 (a maytansinoid). The antibody selectively targets CD19, a surface molecule highly expressed on B-cell malignancies, and upon internalization releases DM4 to disrupt microtubule function, leading to cell cycle arrest and apoptosis. Rituximab is a monoclonal antibody targeting CD20, inducing cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity and complement-mediated lysis. This combination harnesses dual targeting of CD19 and CD20 on B-cells. Clinical trials showed moderate response rates and acceptable toxicity, but the program was terminated due to limited efficacy in heavily pretreated patients[1][3][4].
- Brand names
- coltuximab ravtansine
- Other names
- SAR3419, coltuximab ravtansine + rituximab
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on SAR3419 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR3419 + rituximab.